ライフサイエンスコーパス: CRT

1 CRT doses of 20 to 29.9 Gy (HR, 1.6; 95% CI,1.0 to 2.6)

2 CRT implantation was performed in 552 consecutive patien

3 CRT is associated with improved stage-stratified OS comp

4 CRT reduced the rate of onset of new ventricular arrhyth

5 CRT was associated with a statistically significant impr

6 CRT, BCVA, HbA1c, and prevalence of systemic arterial hy

7 CRT-D (versus ICD) was associated with lower rates of he

8 CRT-D patients with LBBB and complete left-sided reverse

9 CRT-D versus ICD was associated with an improvement in s

10 CRT-D was not associated with significant differences in

11 CRT-D was the most common device type (86.1%), including

12 f CRT-D (10-90 percentile range, 72.9%-98.0% CRT-D).

13 vival were not different between IMRT and 3D-CRT.

14 This study compares 3D-CRT and IMRT outcomes for locally advanced NSCLC in a la

15 onformal external beam radiation therapy (3D-CRT) have not been compared prospectively.

16 ths, fewer patients who received IMRT (vs 3D-CRT) had clinically meaningful decline in FACT-LCS (21%

17 Of 482 patients, 53% were treated with 3D-CRT and 47% with IMRT.

18 alysis was performed to compare IMRT with 3D-CRT in NRG Oncology clinical trial RTOG 0617, in which p

19 erse probability weighted analyses of 26 451 CRT-eligible (ejection fraction </=35, QRS >/=120 ms) pa

20 Visual acuity gain was accompanied by a CRT reduction of -186 mum and -83 mum in the first and t

21 [HR], 1.55 [CI, 1.43 to 1.69]), receipt of a CRT-D device (HR, 1.38 [CI, 1.31 to 1.45]) versus a sing

22 f device implantation, nearly 90% received a CRT-D device.

23 uary 1, 2005, through April 30, 2006) with a CRT-D and confirmed Class I or IIa indications for CRT-D

24 ts with an ICD and 757 (51%) patients with a CRT-D.

25 te this, and limited data comparing adjuvant CRT with CA in US patients, national guidelines endorse

26 Conclusion The use of adjuvant CRT in patients with resected LAHNC with SM negative and

27 M negative and no ECE, 47% received adjuvant CRT.

28 y 59% of surgical patients received adjuvant CRT.

29 c adenocarcinoma patients receiving adjuvant CRT or CA (n = 3008) were identified in the National Can

30 ents received trimodal therapy with adjuvant CRT.

31 lated on MR images acquired before and after CRT by using biexponential fitting.

32 D* values did not significantly change after CRT and were not associated with tumor response to CRT (

33 0.30; 95% CI: 0.12 to 0.78) were lower after CRT-D than after CRT-P in +MWF but not in -MWF.

34 proved clinically (responders) at 6 mo after CRT whereas 19 (28.8%) showed no change in New York Hear

35 ide angiography (ERNA) before and 6 mo after CRT.

36 2 to 0.78) were lower after CRT-D than after CRT-P in +MWF but not in -MWF.

37 All CRT-D patients in LATITUDE remote monitoring (2006-2011)

38 heart failure hospitalization or death among CRT-D (hazard ratio, 1.23; 95% confidence interval, 1.14

39 by adjuvant CT (N = 542), RT (N = 383), and CRT (N = 102).

40 neoadjuvant CT (N = 1332), RT (N = 58), and CRT (N = 1196) followed by surgery or surgery followed b

41 0.14 [B versus A]; HR=0.21 [C versus A]) and CRT-D patients (HR=0.15 [B versus A]; HR=0.23 [C versus

42 Changes in BCVA and CRT associated with edema recurrence upon transition fro

43 ere was a small correlation between BCVA and CRT in pooled AMD trial data (r = -0.24).

44 nd between changes from baseline in BCVA and CRT in pooled AMD trial data.

45 d a convincing relationship between BCVA and CRT.

46 o implantable cardioverter-defibrillator and CRT with defibrillator (CRT-D), respectively (P=0.209).

47 The mean (SD) ages of those in the ICD and CRT-D groups were 67.9 (12.2) years and 68.4 (11.5) year

48 of inappropriate ICD therapy in both ICD and CRT-D patients.

49 clinical stage, demographic information, and CRT regimen.

50 Stratification by mutated MMR gene, sex, and CRT history did not show significantly differential asso

51 At baseline mean VA and CRT were 50.7 letters and 631 mum respectively.

52 ssociated with longer time intervals between CRT completion and surgical procedures.

53 at male sex may be a risk factor for harm by CRT in patients with narrow QRS width, an observation wh

54 ug 31, 2014, 17 666 patients were treated by CRTs-8759 patients in the Camden and Islington trust and

55 aSI increased the cell surface calreticulin (CRT) expression, that is well known for triggering anti-

56 e to conventional concurrent chemoradiation (CRT) therapy and carries a relatively poor prognosis in

57 incter-preserving definitive chemoradiation (CRT) and is typically associated with anogenital human p

58 (LRF) rates after definitive chemoradiation (CRT), associated with anogenital human papilloma virus,

59 ated with use of adjuvant chemoradiotherapy (CRT) for patients with resected locally advanced head an

60 ty of adjuvant concurrent chemoradiotherapy (CRT) for locally advanced or incompletely resected non-s

61 SUMMARY BACKGROUND DATA: Chemoradiotherapy (CRT) response is a predictor of survival in rectal cance

62 e (pCR) after neoadjuvant chemoradiotherapy (CRT) may be a clinical prognostic marker of superior out

63 or combinations of both (chemoradiotherapy, CRT) or surgery alone to identify the most effective app

64 (older adults with multiple comorbidities), CRT-D remained the dominant device type.

65 evel data from 5 randomized trials comparing CRT with no CRT were used to create a prediction model o

66 icated for CRT who had "failed" conventional CRT underwent implantation of an LV endocardial pacing e

67 (n =12), failure to respond to conventional CRT (n = 10), and a high CS pacing threshold or phrenic

68 (CRT) either do not respond to conventional CRT or remain untreated due to an inability or impedimen

69 onization therapy with defibrillator (CRT-D; CRT with implantable cardioverter-defibrillator) was ass

70 onization therapy (CRT) with defibrillation (CRT-D) versus pacing (CRT-P) for patients with nonischem

71 h an implantable cardioverter-defibrillator (CRT-D).

72 teristics associated with CRT defibrillator (CRT-D) use and (2) determine the extent of hospital-leve

73 and in patients with CRT with defibrillator (CRT-D) versus ICD.

74 =230 ms), receipt of CRT with defibrillator (CRT-D) versus implantable cardioverter defibrillator (IC

75 er-defibrillator and CRT with defibrillator (CRT-D), respectively (P=0.209).

76 esynchronization therapy with defibrillator (CRT-D; CRT with implantable cardioverter-defibrillator)

77 ynchronization therapy with a defibrillator [CRT-D], 38.9%).

78 ac resynchronization therapy defibrillators (CRT-D) have a very wide (>/=180 ms) QRS complex duration

79 Primary surgical resection vs definitive CRT.

80 SCCAC is potentially curable with definitive CRT.

81 of 59 mo, 200 participants (43.8%) developed CRTs.

82 The DeltaADC during CRT and four weeks post-CRT were the best predictive par

83 ADC values during CRT and four weeks post-CRT were higher in GR.

84 %) demonstrated a positive echocardiographic CRT response (>/=5% absolute increase in LV ejection fra

85 Accordingly, patients with elevated CRT expression and dense intratumoral infiltration by DC

86 avior and attention problems (externalizing; CRT, no observed; no CRT, 9%); and elevated internalizin

87 ity of patients within an otherwise "failed" CRT population.

88 with heart failure and atrial fibrillation, CRT-D was associated with lower risks of mortality, all-

89 th atrial fibrillation who were eligible for CRT-D and underwent first-time device implantation for p

90 n a national cohort of patients eligible for CRT-D at the time of device implantation, nearly 90% rec

91 A total of 35 patients indicated for CRT who had "failed" conventional CRT underwent implanta

92 ents with heart failure with indications for CRT, those with DCM may not benefit from additional prim

93 and confirmed Class I or IIa indications for CRT-D were matched to implantable cardioverter-defibrill

94 espite having Class I or IIa indications for CRT.

95 class I or IIa guideline recommendations for CRT at the time of device implantation were included in

96 advanced heart failure patients referred for CRT with an LV ejection fraction (EF) of < 35% and QRS >

97 l management of patients with or at risk for CRT.

98 The mean hospital length of stay for CRT decreased, while mean CRT-associated hospital charge

99 hether this was associated with benefit from CRT.

100 to identify all patients receiving care from CRTs in two National Health Service (NHS) mental health

101 Clinician factors associated with greater CRT-D use included clinician implantation volume (OR, 1.

102 In the primary prophylaxis group, CRT-D significantly reduced incidence ventricular arrhyt

103 Treatment with >/= 30 Gy CRT conferred greater risk of internalizing (OR, 1.7; 95

104 56 of 733 assessed patients had CRT based on polymerase chain reaction and sequencing.

105 High CRT expression on tumor cells was associated with a high

106 However, significant disparities in CRT utilization exist in certain demographic subgroups,

107 ng on heart failure (HF) and death events in CRT-D patients with left bundle branch block (LBBB) enro

108 Left ventricular (LV) lead position in CRT may ameliorate mechanisms of MR.

109 DDDR programming in CRT-D patients was associated with improved survival (ad

110 p < 0.001), and every 10% increase in RWT in CRT-D patients was associated with 34% (p = 0.027) and 3

111 cant reduction in inappropriate ICD shock in CRT-D patients.

112 Addressing disparities and variation in CRT-D use among guideline-eligible patients may improve

113 ial volume, and LV dyssynchrony at 1-year in CRT-D patients by comorbidity group.

114 t of system-related complications, including CRT system- and implantation-related events.

115 South London and Maudsley), and longer index CRT episodes (adjusted HR per day 0.996, 0.994-0.998 in

116 verity of psychopathology, duration of index CRT episode, first contact with services, and diagnosis

117 awal, and attention problems (internalizing; CRT, 31%; no CRT, 16%); elevated headstrong behavior and

118 ted States , specifically desktops, laptops, CRT monitors, and flat panel monitors in the decade lead

119 the SCS: disarrangement of plexiform layers, CRT, and multiple adhesion points between retina and ERM

120 (MADIT-CRT: Multicenter Automatic Defibrillator Implantation Wi

121 We examined 1,214 MADIT-CRT (Multicenter Automatic Defibrillator Implantation Tr

122 bundle branch block (LBBB) enrolled in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Tr

123 In MADIT-CRT, >20% of CRT-D patients exhibited discordant reverse

124 During long-term follow-up of MADIT-CRT study patients with LBBB randomized to CRT-D, there

125 thmia (VA) in patients enrolled in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Tr

126 studied 1064 patients enrolled in the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantat

127 ith Cardiac Resynchronization Therapy (MADIT-CRT) study by QRS duration or morphology further stratif

128 ith Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271).

129 ith Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271).

130 length of stay for CRT decreased, while mean CRT-associated hospital charges increased progressively

131 domain optical coherence tomography-measured CRT of 387 eyes of 345 patients enrolled in 6 prospectiv

132 Neoadjuvant CRT followed by surgery compared with surgery alone was

133 on developing the most effective neoadjuvant CRT regimens for both adenocarcinomas and squamous cell

134 owed a superior effectiveness of neoadjuvant CRT and surgery compared with surgery alone (HR = 0.77,

135 his network meta-analysis showed neoadjuvant CRT followed by surgery to be the most effective strateg

136 After this neoadjuvant CRT, surgical exploration is undertaken 6 to 8 weeks lat

137 In patients with NICM, CRT-D was superior to CRT-P in +MWF but not -MWF.

138 ention problems (internalizing; CRT, 31%; no CRT, 16%); elevated headstrong behavior and attention pr

139 izing symptoms (global symptoms; CRT, 6%; no CRT, 5%).

140 ified: no significant symptoms (CRT, 63%; no CRT, 70%); elevated anxiety and/or depression, social wi

141 mpared across radiation treatment groups (no CRT, focal irradiation, craniospinal irradiation) using

142 roblems (externalizing; CRT, no observed; no CRT, 9%); and elevated internalizing and externalizing s

143 d risk of severe impairment compared with no CRT (eg, intelligence: RR = 2.70; 95% CI, 1.37 to 5.34;

144 om 5 randomized trials comparing CRT with no CRT were used to create a prediction model of change in

145 as worse after upgrade compared with de novo CRT defibrillator implantations (hazard ratio, 1.65; 95%

146 of upgrade procedures compared with de novo CRT.

147 In MADIT-CRT, >20% of CRT-D patients exhibited discordant reverse remodeling i

148 e general population, even in the absence of CRT, and is associated with disrupted attainment of adul

149 marked heterogeneity of treatment benefit of CRT that can be predicted based on baseline QoL, age, an

150 ect to comorbidity burden and the benefit of CRT-D versus ICD only for death or nonfatal HF events (i

151 multiple comorbidities with the benefits of CRT over implantable cardioverter-defibrillator (ICD) al

152 Survival benefits of CRT versus RT alone increased in patients with multiple

153 ppear to compromise the clinical benefits of CRT-D compared with ICD alone.

154 and 99 or more days) from the completion of CRT to surgical resection, adjusted for clinical stage,

155 Complications of CRT include pulmonary embolism, recurrent deep venous th

156 s duplex is recommended for the diagnosis of CRT.

157 rillator only therapy, whereas the effect of CRT-D in patients from the upper quartiles group (QRS>13

158 The real-world comparative effectiveness of CRT-D (versus ICD) is significantly less among patients

159 y along with increased surface expression of CRT.

160 We examined the influence of CRT on ventricular arrhythmias in patients with primary

161 ied baseline QoL, age, and an interaction of CRT with QRS duration as predictors of QoL benefits 3 mo

162 election factor for further investigation of CRT in such patients.

163 ted change in these parameters after 6 mo of CRT.

164 The highest number of CRT devices were implanted in the 65- to 84-year age gro

165 .6%), with significant increase in number of CRT implants in older patients >/= 85 years over the yea

166 Outcomes of CRT-D in these patients are not well-established because

167 Multivariate predictors of CRT-D implant included demographic, clinical, and geogra

168 gic thromboprophylaxis for the prevention of CRT remains to be established.

169 the overall median risk-standardized rate of CRT-D use was 79.9% (range, 26.7%-100%; median OR, 2.08;

170 rolonged PR interval (>/=230 ms), receipt of CRT with defibrillator (CRT-D) versus implantable cardio

171 nt-related factors can influence the risk of CRT.

172 ic-targeting LV lead strategy at the time of CRT implant.

173 ient risk with device benefit at the time of CRT implantation.

174 welling CVAD is recommended for treatment of CRT.

175 Little is known about the use of CRT in combination with an implantable cardioverter defi

176 The use of CRT varied substantially according to several factors, i

177 ficant interhospital variation in the use of CRT-D (10-90 percentile range, 72.9%-98.0% CRT-D).

178 s independently associated with lower use of CRT-D (odds ratio [OR], 0.77; 95% CI, 0.71-0.83) as was

179 nt of hospital-level variation in the use of CRT-D among guideline-eligible patients undergoing ICD p

180 ter accounting for these factors, the use of CRT-D continued to vary widely by hospital.

181 However, use of CRT-D differed by race and implanting operator character

182 s, were used to calculate HRs and 95% CIs of CRTs by ADII tertile.

183 An important process in the development of CRTs is inflammation, which has been shown to be modulat

184 s by mutated MMR gene, sex, and a history of CRTs.

185 matory potential of the diet and the risk of CRTs in persons with LS.We used the dietary intake of 45

186 ve surgery and adjuvant radiotherapy (RT) or CRT.

187 implantable cardioverter-defibrillator over CRT, according to underlying heart disease, in a large s

188 ) with defibrillation (CRT-D) versus pacing (CRT-P) for patients with nonischemic cardiomyopathy (NIC

189 ce of edema is anticipated in many patients, CRT appears strongly correlated with loss of BCVA in RVO

190 Post-CRT ADCs and values of ADC changes accurately identify n

191 Post-CRT and ADC change measurements achieved negative predic

192 ormance in determining CR from pre- and post-CRT ADCs and ADC change.

193 ally advanced rectal cancer on pre- and post-CRT images.

194 77% (48 of 62), and 61% (38 of 62) for post-CRT, 79% (49 of 62), 86% (53 of 62), and 60% (37 of 62)

195 The post-CRT changes in QRS duration (P = 0.006), echocardiograph

196 ADC values during CRT and four weeks post-CRT were higher in GR.

197 The DeltaADC during CRT and four weeks post-CRT were the best predictive parameters for pathological

198 Pre-CRT ADC values were lower in good versus moderate/poor r

199 increase (DeltaADC) compared to the ADC pre-CRT was higher in GR (P < 0.001).

200 Preoperative CRT followed by total mesorectal excision (TME) is the s

201 ood treatment responders during preoperative CRT for locally advanced rectal cancer.

202 denocarcinoma were treated with preoperative CRT followed by surgery.

203 rs is the best available approach to prevent CRT.

204 bidity attributable to cranial radiotherapy (CRT) -associated meningiomas.

205 of 63506 eligible patients (88.6%) received CRT-D at the time of device implantation.

206 ved upfront surgery and 584 (55.9%) received CRT.

207 ge I to III SCCAC and HIV infection received CRT: 45 to 54 Gy radiation therapy to the primary tumor

208 In both groups, 58% of the patients received CRT.

209 patients with stage I to III SCCAC received CRT including cisplatin, fluorouracil, and radiation the

210 versus 38.5 months for patients who received CRT (log-rank P = .42).

211 versus 40.4 months for patients who received CRT in cohort one (log-rank P < .001).

212 fibrillator compared with those who received CRT without a defibrillator (hazard ratio for mortality

213 e weighting for the probability of receiving CRT-D, risks of mortality (hazard ratio, 0.83; 95% confi

214 mined overall survival of patients receiving CRT versus RT.

215 with ICM had better survival when receiving CRT with a defibrillator compared with those who receive

216 Successful CRT using coronary venous pacing depends on appropriate

217 es were identified: no significant symptoms (CRT, 63%; no CRT, 70%); elevated anxiety and/or depressi

218 and externalizing symptoms (global symptoms; CRT, 6%; no CRT, 5%).

219 on with Candidatus Rickettsia tarasevichiae (CRT) was first reported in northeastern China in 2012.

220 Crisis resolution and home treatment teams (CRTs) offer an alternative to hospital admission for pat

221 ector memory T-cell subsets, suggesting that CRT triggers the activation of adaptive immune responses

222 The CRT improved by 123 mum, 146 mum, and 166 mum in the Mon

223 o acute services within 1 year of seeing the CRT.

224 Information on cranial radiation therapy (CRT) doses and parameters of delivery were abstracted fr

225 combined chemotherapy and radiation therapy (CRT) in patients with rectal cancer.

226 gible for cardiac resynchronization therapy (CRT) either do not respond to conventional CRT or remain

227 regarding cardiac resynchronization therapy (CRT) in patients with multiple comorbidities are limited

228 Cardiac resynchronization therapy (CRT) is a potent treatment for heart failure in the sett

229 nefits of cardiac resynchronization therapy (CRT) on morbidity and mortality in selected patients are

230 dates for cardiac resynchronization therapy (CRT) receive either a biventricular pacemaker or a biven

231 ated that cardiac resynchronization therapy (CRT) reduced both mortality and heart failure hospitaliz

232 Cardiac resynchronization therapy (CRT) reduces the risk for mortality and heart failure-re

233 enefit of cardiac resynchronization therapy (CRT) with defibrillation (CRT-D) versus pacing (CRT-P) f

234 enefit of cardiac resynchronization therapy (CRT), but estimating benefit for individual patients rem

235 sponse to cardiac resynchronization therapy (CRT).

236 receiving cardiac resynchronization therapy (CRT).

237 t despite cardiac resynchronization therapy (CRT).

238 [including SND]); central retinal thickness (CRT [excluding SND]); choroidal thickness (CT); nasal an

239 al acuity (BCVA), central retinal thickness (CRT) and concomitant medication at month 6 were defined

240 acuity (BCVA) and central retinal thickness (CRT) in eyes receiving ranibizumab for 3 common retinal

241 uity (BCVA), mean central retinal thickness (CRT), number of injections from baseline to 1 year, and

242 ous access device (CVAD)-related thrombosis (CRT) is a common complication among patients requiring c

243 = 13), and complete responders (CR = 14) to CRT, as defined by a tumor regression score, were examin

244 4 patients were randomized to ICD and 880 to CRT-D.

245 ma, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC.

246 CC, we hypothesized that adding cetuximab to CRT would reduce LRF in SCCAC.

247 ures from single- or dual-chamber devices to CRT is increasing, there are only sparse data on the out

248 lusion Childhood cancer survivors exposed to CRT and subsequently diagnosed with a meningioma experie

249 and Methods From 4,221 survivors exposed to CRT in the Childhood Cancer Survivor Study, a diagnosis

250 ptimization of these factors, nonresponse to CRT may occur in one-third of patients, which has led to

251 nderwent cardiac magnetic resonance prior to CRT device implantation.

252 lar arrhythmias among patients randomized to CRT-D versus implantable cardioverter defibrillator (ICD

253 T-CRT study patients with LBBB randomized to CRT-D, there were differences in HF or death risk and in

254 in EchoCRT was observed in men randomized to CRT-ON; the comparison with women did not reach statisti

255 sk of death (HR 1.29, P < 0.001) relative to CRT.

256 d were not associated with tumor response to CRT (P > .36).

257 Response to CRT seems to increase as the QRS duration becomes longer

258 prove to be useful in predicting response to CRT.

259 In patients with NICM, CRT-D was superior to CRT-P in +MWF but not -MWF.

260 as to determine whether CRT-D is superior to CRT-P in patients with NICM either with (+) or without (

261 s. 66 letters, P < 0.001); higher mean total CRT (mum) on OCT (514 vs. 472 vs. 404, P < 0.001); and g

262 fetime risk of developing colorectal tumors (CRTs) because of a germline mutation in one of their mis

263 l were less favorable in patients undergoing CRT upgrade compared to de novo implantations.

264 Patients undergoing CRT were less likely to have a decrement in their QoL (2

265 In patients undergoing CRT, longer QLV was an independent predictor of MR reduc

266 ained ventricular arrhythmias, who underwent CRT implantation with (n = 4,037) or without (n = 1,270)

267 ed in patients undergoing de novo or upgrade CRT defibrillator implantation at 3 implant centers in G

268 in patients receiving de novo versus upgrade CRT defibrillator therapy.

269 n treated with primary surgical resection vs CRT.

270 e OPSCC when treated with primary surgery vs CRT.

271 e aim of this study was to determine whether CRT-D is superior to CRT-P in patients with NICM either

272 The WiSE-CRT system (EBR Systems, Sunnyvale, California) was deve

273 trates the clinical feasibility for the WiSE-CRT system, and provided clinical benefits to a majority

274 ssing the safety and performance of the WiSE-CRT system.

275 and hospital characteristics associated with CRT defibrillator (CRT-D) use and (2) determine the exte

276 not seem to be significantly associated with CRT risk in persons with LS.

277 We determined factors associated with CRT use and examined overall survival of patients receiv

278 the absolute risk reduction associated with CRT-D over ICD alone appeared greater than that seen for

279 phology did not derive clinical benefit with CRT-D during long-term follow-up.

280 had a greater adjusted survival benefit with CRT-D versus standard ICD (hazard ration [HR] for death:

281 ociated with increased OS when compared with CRT (adjusted hazard ratio [HR], 1.01; 95% CI, 0.74-1.39

282 n increased risk of meningioma compared with CRT doses of 1.5 to 19.9 Gy ( P < .001).

283 ed associated with improved OS compared with CRT in cohort one (hazard ratio, 1.35; P = .019), and th

284 th lower LRF rates than historical data with CRT alone, toxicity was substantial, and LRF still occur

285 ed risk for HF hospitalization or death with CRT-D versus implantable cardioverter-defibrillator only

286 ival and heart failure hospitalizations with CRT-D were greatest in patients with a QRSD >/=180 ms wi

287 fidence interval, 0.62-0.76) were lower with CRT-D compared with ICD alone.

288 -weighted estimates to compare outcomes with CRT-D versus ICD alone.

289 y group in all patients and in patients with CRT with defibrillator (CRT-D) versus ICD.

290 his study examined outcomes in patients with CRT-D in a very wide QRSD with left bundle branch block

291 d prolonged PR (>230 ms) were protected with CRT-D (HR=0.31, P=0.003), whereas the association was ne

292 ted with a significantly increased risk with CRT-D relative to implantable cardioverter-defibrillator

293 out LBBB had no improvement in survival with CRT-D, and those with a QRSD 150 to 179 ms and LBBB had

294 re hospitalizations longer than 4 years with CRT-D versus standard ICDs based on a QRSD and morpholog

295 ealth services within 1 year of contact with CRTs.

296 f relapse and readmission after contact with CRTs.

297 s for future relapse after interactions with CRTs.

298 es in quality of life (QoL) with and without CRT.

299 Implantation of an ICD with or without CRT.

300 overter-defibrillator (ICD) patients without CRT despite having Class I or IIa indications for CRT.